Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cognition, Function, and Disability in Patients with Schizophrenia: A Review of Longitudinal Studies
Tarek K. Rajji, Dielle Miranda, Benoit H. Mulsant
The Canadian Journal of Psychiatry (2014) Vol. 59, Iss. 1, pp. 13-17
Open Access | Times Cited: 116

Showing 1-25 of 116 citing articles:

Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia
Maren Carbon, Christoph U. Correll
CNS Spectrums (2014) Vol. 19, Iss. S1, pp. 35-53
Closed Access | Times Cited: 214
Cognitive impairment in people with schizophrenia: an umbrella review
Yohannes Gebreegziabhere, Kassahun Habatmu, Awoke Mihretu, et al.
European Archives of Psychiatry and Clinical Neuroscience (2022) Vol. 272, Iss. 7, pp. 1139-1155
Open Access | Times Cited: 146
Detecting schizophrenia at the level of the individual: relative diagnostic value of whole-brain images, connectome-wide functional connectivity and graph-based metrics
Du Lei, Walter Hugo Lopez Pinaya, Thérèse van Amelsvoort, et al.
Psychological Medicine (2019) Vol. 50, Iss. 11, pp. 1852-1861
Open Access | Times Cited: 95
Integrating machining learning and multimodal neuroimaging to detect schizophrenia at the level of the individual
Du Lei, Walter Hugo Lopez Pinaya, Jonathan Young, et al.
Human Brain Mapping (2019) Vol. 41, Iss. 5, pp. 1119-1135
Open Access | Times Cited: 83
Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis
Sakiko Tsugawa, Yoshihiro Noda, Ryosuke Tarumi, et al.
Journal of Psychopharmacology (2019) Vol. 33, Iss. 10, pp. 1199-1214
Closed Access | Times Cited: 80
Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia
Chadia Haddad, Pascale Salameh, Hala Sacre, et al.
BMC Psychiatry (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 28
The risk of Alzheimer's disease and cognitive impairment characteristics in eight mental disorders: A UK Biobank observational study and Mendelian randomization analysis
Yiliang Liu, Xuewen Xiao, Yang Yang, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 7, pp. 4841-4853
Open Access | Times Cited: 13
Is It Possible to Predict the Future in First-Episode Psychosis?
Jaana Suvisaari, Outi Mantere, Jaakko Keinänen, et al.
Frontiers in Psychiatry (2018) Vol. 9
Open Access | Times Cited: 83
Converging models of schizophrenia – Network alterations of prefrontal cortex underlying cognitive impairments
Takeshi Sakurai, Nao J. Gamo, Takatoshi Hikida, et al.
Progress in Neurobiology (2015) Vol. 134, pp. 178-201
Open Access | Times Cited: 82
Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort
Anja P. Husa, Jani Moilanen, Graham K. Murray, et al.
Psychiatry Research (2016) Vol. 247, pp. 130-138
Open Access | Times Cited: 82
Cognitive and functional deficits in people with schizophrenia: Evidence for accelerated or exaggerated aging?
Philip D. Harvey, Jennifer B. Rosenthal
Schizophrenia Research (2017) Vol. 196, pp. 14-21
Closed Access | Times Cited: 70
Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia: relationships with clinical phenotypes and cognitive deficits
D. C. Chen, Xin Du, Guo-He Yin, et al.
Psychological Medicine (2016) Vol. 46, Iss. 15, pp. 3219-3230
Closed Access | Times Cited: 65
Feasibility and outcomes of a multi-function mobile health approach for the schizophrenia spectrum: App4Independence (A4i)
Sean A. Kidd, Laura Feldcamp, Amos Adler, et al.
PLoS ONE (2019) Vol. 14, Iss. 7, pp. e0219491-e0219491
Open Access | Times Cited: 55
Use of the Chinese version of the MATRICS Consensus Cognitive Battery to assess cognitive functioning in individuals with high risk for psychosis, first-episode schizophrenia and chronic schizophrenia: a systematic review and meta-analysis
Bing Cai, Yikang Zhu, Dongyang Liu, et al.
The Lancet Regional Health - Western Pacific (2024) Vol. 45, pp. 101016-101016
Open Access | Times Cited: 7
The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy
Kenya A. Costa-Dookhan, Sri Mahavir Agarwal, Araba Chintoh, et al.
Expert Opinion on Drug Safety (2019) Vol. 19, Iss. 1, pp. 43-57
Closed Access | Times Cited: 48
Alzheimer´s Disease associated with Psychiatric Comorbidities
Michelle Lima Garcez, Ana Carolina Brunatto Falchetti, Francielle Mina, et al.
Anais da Academia Brasileira de Ciências (2015) Vol. 87, Iss. 2 suppl, pp. 1461-1473
Open Access | Times Cited: 49
Assessing the potential of longitudinal smartphone based cognitive assessment in schizophrenia: A naturalistic pilot study
Gang Liu, Philip Henson, Matcheri S. Keshavan, et al.
Schizophrenia Research Cognition (2019) Vol. 17, pp. 100144-100144
Open Access | Times Cited: 36
Assessment of functioning and disability in patients with schizophrenia using the WHO Disability Assessment Schedule 2.0 in a large-scale database
Ruey Chen, Tsan‐Hon Liou, Kwang-Hwa Chang, et al.
European Archives of Psychiatry and Clinical Neuroscience (2017) Vol. 268, Iss. 1, pp. 65-75
Closed Access | Times Cited: 34
Disparate effects of first and second generation antipsychotics on cognition in schizophrenia – Findings from the randomized NeSSy trial
Tanja Veselinović, Martin Scharpenberg, Martin Heinze, et al.
European Neuropsychopharmacology (2019) Vol. 29, Iss. 6, pp. 720-739
Closed Access | Times Cited: 34
Risk of dementia associated with psychotic disorders in later life: the health in men study (HIMS)
Osvaldo P. Almeida, Andrew H. Ford, Graeme J. Hankey, et al.
Psychological Medicine (2018) Vol. 49, Iss. 2, pp. 232-242
Closed Access | Times Cited: 33
<p>Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia</p>
Maju Mathews, Srihari Gopal, Isaac Nuamah, et al.
Neuropsychiatric Disease and Treatment (2019) Vol. Volume 15, pp. 1365-1379
Open Access | Times Cited: 32
Verbal learning deficits associated with increased anticholinergic burden are attenuated with targeted cognitive training in treatment refractory schizophrenia patients
Yash B. Joshi, Michael L. Thomas, William C. Hochberger, et al.
Schizophrenia Research (2019) Vol. 208, pp. 384-389
Open Access | Times Cited: 31
Proxy measures of premortem cognitive aptitude in postmortem subjects with schizophrenia
Jill R. Glausier, Mary Ann Kelly, Samantha Salem, et al.
Psychological Medicine (2019) Vol. 50, Iss. 3, pp. 507-514
Open Access | Times Cited: 30
Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia
Tanja Veselinović, Irene Neuner
CNS Drugs (2022) Vol. 36, Iss. 8, pp. 819-858
Open Access | Times Cited: 18
Sensory disturbances, inhibitory deficits, and the P50 wave in schizophrenia
Petr Bob, Přemysl Vlček, J Raboch
Neuropsychiatric Disease and Treatment (2014), pp. 1309-1309
Open Access | Times Cited: 32
Page 1 - Next Page

Scroll to top